Oral extended release of dexamethasone: Montmorillonite–PLGA nanocomposites as a delivery vehicle
Source abstract
Abstract
Abstract Dexamethasone (DEX) is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. It is 25 times more potent than cortisol in its glucocorticoid effect, while having a minimal mineralocorticoid effect. Due to the hydrophobicity and short half-life of the drug, high doses are required to maintain its therapeutic level in the blood plasma which has undesirable side effects. Therefore, a new drug delivery system capable of overcoming the drawbacks associated with dexamethasone is required at present. The present study is aimed at developing an extended release carrier for DEX using montmorillonite (Mt) and polylactic-co-glycolic acid (PLGA) nanocomposites suitable for oral administration. The synthesized clay polymer nanocomposites (CPN) were characterized with respect to morphology, particle size, physical status etc. The in-vitro drug release behavior of DEX from Mt–PLGA nanocomposites and PLGA particles in simulated gastrointestinal fluids has been investigated. In-vitro drug release profiles of CPN in simulated gastrointestinal fluid indicate an extended release of DEX as compared to DEX–PLGA particles and pure DEX.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Hydrogels: synthesis, properties, applications · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. Use of clays as drug delivery systems: possibilities and limitations10.1016/j.clay.2006.06.015 ↗
2. Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model10.1016/j.ijpharm.2013.07.010 ↗
3. Introduction to clay polymer nanocomposites (CPN) (Chapter 13)
4. A validated, stability-indicating HPLC method for the determination of dexamethasone related substances on dexamethasone-coated drug-eluting stents10.1016/j.jpba.2008.07.010 ↗
5. Functional polymeric nanoparticles for dexamethasone loading and release10.1016/j.colsurfb.2011.12.008 ↗
6. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles10.1016/j.ijpharm.2006.11.028 ↗
7. Knockout of the vascular endothelial glucocorticoid receptor abrogates dexamethasone-induced hypertension10.1097/HJH.0b013e328347da54 ↗
8. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study
9. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices10.1016/S0142-9612(01)00291-5 ↗
10. Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis10.1186/1471-2474-8-12 ↗
11. Fate of L-DOPA in the presence of inorganic matrices: vectorization or composite material formation?10.1021/jp205050k ↗
12. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices10.1016/S0142-9612(00)00115-0 ↗
13. Montmorillonite–PLGA nanocomposites as an oral extended drug delivery vehicle for venlafaxine hydrochloride10.1016/j.clay.2014.06.006 ↗
14. Naturally occurring clay, montmorillonite, as a drug delivery vehicle for in vitro extended release of venlafaxine hydrochloride
15. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery10.1016/S0168-3659(02)00009-3 ↗
16. Synthesis and characterization of biodegradable clay–polymer nanocomposites for oral sustained release of anti-inflammatory drug
17. In vitro release of sodium diclofenac from poloxamer 188 modified montmorillonite as an oral drug delivery vehicle
18. Diclofenac sodium adsorption onto montmorillonite: adsorption equilibrium studies and drug release kinetics10.1260/0263-6174.32.5.365 ↗
19. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery10.1016/j.biomaterials.2005.12.021 ↗
20. Steroid nanocrystals prepared using the nano-spray dryer B-9010.3390/pharmaceutics5010107 ↗
21. Smectites–polymer nanocomposites (Chapter 13.1)
22. Green nanocomposites: synthesis and characterization10.1166/jnn.2007.698 ↗
23. Preparation of 5-fluorouracil-loaded poly(l-lactide-co-glycolide) wafer and evaluation of in vitro release behaviour10.1007/BF03218350 ↗
24. In vitro degradation of nanoparticles prepared from polymers based on DL-lactide, glycolide and poly(ethylene oxide)10.1016/j.jconrel.2004.09.008 ↗
25. Predictors of glass transition in the biodegradable polylactide and poly-lactide-co-glycolide polymers10.1002/app.22135 ↗
26. The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis10.1016/j.biomaterials.2012.08.008 ↗
27. Sustained release of venlafaxine from venlafaxine–montmorillonite–polyvinylpyrrolidone composites10.1016/j.clay.2010.11.013 ↗
28. Anti-inflammatory action of glucocorticoids—new mechanisms for old drugs10.1056/NEJMra050541 ↗
29. A review of block polymer surfactants10.1007/BF02894385 ↗
30. In vitro sustained delivery of atenolol, an antihypertensive drug using naturally occurring clay mineral montmorillonite as a carrier
31. Clay–polymer nanocomposites as a novel drug carrier: synthesis, characterization and controlled release study of propranolol hydrochloride10.1016/j.clay.2013.06.009 ↗
32. MMT–PLGA nanocomposites as an oral and controlled release carrier for 5-fluorouracil: a novel approach
33. Organoclay Pluronic F68–montmorillonite, as a sustained release drug delivery vehicle for propranolol hydrochloride
34. Till · 2011
35. Polymeric delivery systems for dexamethasone10.1016/j.lfs.2013.12.020 ↗
36. Corticosteroids for acute bacterial meningitis10.1002/14651858.CD004405.pub2 ↗
37. Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations10.1016/j.jpba.2004.01.012 ↗
38. World Health Organization · 2013
39. Poly(trimethylene carbonate) and monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate) nanoparticles for the controlled release of dexamethasone10.1016/j.jconrel.2005.12.001 ↗